Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Abroad (travel likely)RecruitingPHASE1

Conditions

EGFR Gene Mutation · Glioblastoma · MGMT-Unmethylated Glioblastoma · Recurrent Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California, San Francisco, San Francisco, California, United States
Contact: Study coordinator (Neuro-Oncology New Patient Coordinator) · NeuroOncNewPatientCoord@ucsf.edu · 877-827-3222
Study coordinator · cancertrials@ucsf.edu
Contact: Principal Investigator (Jennifer Clarke, MD, MPH)
Hideho Okada, MD, PhD (Sub-investigator)

Study leads

Jennifer Clarke, MD, MPH
Study Chair
University of California, San Francisco

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Epidermal Growth Factor · Epidermal Growth Factor Receptor · Epidermal Growth Factor Receptor Gene Mutation

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States · East Brunswick, United States

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer Metastatic · EGFR Gene Mutation

Abroad (travel likely)RecruitingPHASE1

San Francisco, United States

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer · Non Small Cell Lung Cancer Metastatic · Non Small Cell Lung Cancer NSCLC

Abroad (travel likely)Recruiting

Aix-en-Provence, France · Bobigny, France

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Lung Cancer Stage III · Mutation

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China